Simultaneous occurrence of a t(9;22) (Ph) with a t(2;11) in a patient with CML and emergence of a new clone with the t(2;11) alone after imatinib mesylate treatment.
Royer-Pokora
B
B
Hildebrandt
B
B
Redmann
A
A
Herold
C
C
Kronenwett
R
R
Haas
R
R
Drechsler
M
M
Wieland
C
C
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002880:Chromosomes, Human, Pair 11 / Q000648:ultrastructure*; D002889:Chromosomes, Human, Pair 2 / Q000648:ultrastructure*; D017326:Clinical Trials, Phase III as Topic; D002999:Clone Cells / Q000648:ultrastructure; D004268:DNA-Binding Proteins / Q000235:genetics; D018450:Disease Progression; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors; D011495:Histone-Lysine N-Methyltransferase; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D051788:Myeloid-Lymphoid Leukemia Protein; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use*; D011519:Proto-Oncogenes; D011743:Pyrimidines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D014157:Transcription Factors; D014178:Translocation, Genetic
D000970:Antineoplastic Agents; D001549:Benzamides; D004268:DNA-Binding Proteins; D004791:Enzyme Inhibitors; C497422:KMT2A protein, human; D010879:Piperazines; D011743:Pyrimidines; D014157:Transcription Factors; D051788:Myeloid-Lymphoid Leukemia Protein; D000068877:Imatinib Mesylate; D011495:Histone-Lysine N-Methyltransferase; D016044:Fusion Proteins, bcr-abl; D006918:Hydroxyurea